Background: Expression and secretion of complement C3 is positively regulated in hepatocytes during acute inflammation. Results: Activation of PPAR␣ stimulates C3 expression but interferes with up-regulation of C3 gene by TNF␣-NF-B axis.
The complement system is evolutionary conserved machinery, including ϳ30 circulating and cell membranebound proteins interacting with one another during complement activation. Complement activation is realized through the intermediary of three activation cascades: the classic, alternative, and lectin pathways. Complement C3 is a central protein that is indispensable for all complement activation cascades (1) . In addition to its role in complement activation, C3 and its degradation products are able to promote phagocytosis, activate inflammatory responses against pathogens, and regulate differentiation and maturation of B-and T-lymphocytes and dendritic cells (2) . The main source of C3 in human is the liver (hepatocytes) (3), but C3 is also expressed in mononuclear phagocytes (4) , vascular endothelium (5), astroglia (6) , and adipocytes (7) . C3 is an acute phase protein, and its plasma concentrations increases at the early steps of acute inflammation. Such agents as LPS and proinflammatory cytokines IL-1␤, IL-6, and TNF␣ stimulate C3 gene expression in C3 producing cells (8) . IL-1␤ and TNF␣ are the main positive regulators of C3 expression during acute response in hepatocytes (9, 10) . C3 expression was also shown to be activated by inflammatory stimuli in tissue macrophages and the amplitude of the response in terms of the level of C3 gene activation is significantly higher (5-30-fold) in those cells than in hepatocytes (11) (12) (13) . Nevertheless, the mechanism of C3 gene up-regulation in the liver and macrophages by proinflammatory cytokines is not elucidated enough.
In addition to immune functions of C3, emerging evidence shows cross-regulation between C3 and several metabolic pathways. Indeed, C3 and the products of its hydrolysis (C3a and the product of C-terminal desargination of C3a (C3ades-Arg, also known as acylation stimulating protein) are involved in regulation of fat tissue and lipid metabolism (14, 15) . Acylation stimulating protein and C3a enhance fat storage into adipocytes by increasing triglyceride synthesis and decreasing intracellular lipolysis (16) Importance of C3 for lipid metabolism is argued by observation that C3 knock-out mice, which also have defects in apolipoprotein E and low density lipoprotein receptor genes (C3 (17) . Moreover, a high level of C3 in plasma was shown to be a risk factor for cardiovascular diseases and atherosclerosis in human (18, 19) .
Currently, detailed mechanisms coordinating lipid metabolism and C3 expression in hepatocytes and macrophages are not studied. Metabolic control of gene regulation involves several pathways, including nonsteroid nuclear receptors. Nuclear receptor superfamily consists of transcription factors, which regulate gene expression in ligand-dependent manner (20) . The nuclear receptors such as peroxisome proliferator-activated receptors (PPARs), 3 liver X receptors, and other not only modify lipid metabolism but also regulate inflammation in different cell types and tissues (21) . Thereby, those nuclear receptors may serve as common regulators for both metabolic processes and immune gene expression.
To date, the farnesoid X receptor, nuclear receptor that utilizes bile acids as a ligand, is shown to regulate C3 gene in hepatocytes (22) . Recently, we have found that the C3 gene is the direct target for regulation by liver X receptors in human macrophages (23) . Taken together, these data show a possibility that C3 gene expression is coordinated by several metabolic products via nuclear receptor activation.
PPAR␣ is a member of nuclear receptor superfamily that is expressed in tissues with high rates of fatty acid oxidation such as the liver (24) . PPAR␣ can be activated by a variety of endogenous ligands such as long-chain polyunsaturated fatty acids, eicasonoids, prostaglandins D1 and D2 and leukotrien B4 (25) (26) (27) . PPAR␣ is also a target for synthetic PPAR␣ agonists such as fibrates. In the liver, PPAR␣ directly regulates multitude of genes involved in control of lipid metabolism and fatty acid oxidation in the liver (24) . Moreover, PPAR␣ demonstrates an anti-inflammatory potential in macrophages and other tissues by negatively interacting with AP-1 and NF-B signaling pathways (28) .
In this article, we show that C3 expression is up-regulated by PPAR␣ through PPAR response element (PPRE) within the human C3 promoter in HepG2 cells. We found that TNF␣ stimulates C3 gene expression via NF-B by increasing of p65 binding with the human C3 promoter and, to a lesser extent, through MEK1/2 signaling pathways in HepG2 cells. Liganddependent activation of PPAR␣ inhibits TNF␣-mediated stimulation of the C3 gene, and the PPRE is necessary for this antiinflammatory effect of PPAR␣ towards the C3 gene. Moreover, we show physical interaction of PPAR␣ with p65 within the C3 promoter, which may explain PPRE-dependent mechanism of PPAR␣-NF-B interference in the regulation of C3 transcription. On the contrary, TNF␣ decreases PPAR␣ protein expression and binding with the PPRE into the human C3 promoter, thereby forming TNF␣-PPAR␣ negative feedback loop in the regulation of the C3 gene. We also show that treatment of mice with the PPAR␣ agonist WY-14643 leads to an increase of C3 expression but abrogates LPS-induced up-regulation of C3 transcription in the mouse liver. Taken together, these results show the mechanism evolutionary conserved among mammalians of PPAR␣-dependent activation of C3 expression in the liver and elucidate involvement of PPAR␣ in the control of the C3 gene in acute phase of inflammation.
EXPERIMENTAL PROCEDURES
Chemical Inhibitors, Synthetic Ligands, Recombinant and Purified Proteins-The following MAPK inhibitors and NF-B inhibitor were purchased from Biomol: SB203580 (p38 inhibitor, catalog no. EI-286); JNK1/2/3 inhibitor (catalog no. EI-305); U0126 (MEK1/2 inhibitor, catalog no. EI-282); and QNZ (NF-kB inhibitor, catalog no. EI-352). PPAR␣ ligands WY-14643 (catalog no. C7081) and MK-886 (catalog no. M2692) were purchased from Sigma. Human recombinant TNF␣ was purchased from Sigma (catalog no. T0157).
Antibodies-Mouse monoclonal antibodies against human ␤-actin (catalog no. ab3280), against human PPAR␣ (catalog no. ab2779) were purchased from Abcam. Rabbit polyclonal antibodies against human p65 (catalog no. sc-372) was purchased from Santa Cruz Biotechnology.
Plasmid Construction and Site-directed Mutagenesis-Primers 5Ј-ctcgagTCATTCCCAACCTGCTAACC-3Ј and 5Ј-ggtaccGGTTACTCACCCCATGGACA-3Ј (restriction sites for XhoI and KpnI, respectively, are underlined) were used to amplify the Ϫ166 to ϩ268 region of the human C3 promoter. Amplified fragment was ligated into pAT-TA vector (Eurogen) and cloned into pGL3Basic luciferase-containing reporter plasmid (Promega), digested by XhoI and KpnI restrictases. Constructed plasmid pC3(Ϫ166/ϩ268)-Luc, containing the luciferase gene under control of the Ϫ166 to ϩ268 region of the human C3 promoter, was verified by sequencing. Plasmids, containing Ϫ463 to ϩ268 (pC3(Ϫ463/ϩ268)-Luc) and Ϫ310 to ϩ268 (pC3(Ϫ310/ϩ268)-Luc) region of the human C3 promoter linked with luciferase gene, were described (23) . Mutagenesis on DR0 site (Ϫ235 to Ϫ224 compared with transcription initiation point of the human C3 gene) within pC3(Ϫ310/ϩ268)-Luc was generated with QuikChange sitedirected mutagenesis kit (Stratagene) using the following oligonucleotide (direct chain is shown): 5Ј-TGCCCTGGACTCT-CCCATTGTCATTGCCACCTGGTGAACACA-3Ј and the corresponding antisense oligonucleotide (the changed nucleotides are underlined). The final plasmid, containing described mutations in DR0 site pC3(Ϫ310/ϩ268)DR0mut-Luc, was sequenced to confirm the efficiency of site-directed mutagenesis.
Cell Cultures and Transfection-The human acute monocytic leukemia cell line THP-1 and human hepatoma cell line HepG2 were obtained from the Cell Culture Bank of the Institute of Cytology, Russian Academy of Sciences (St. Petersburg, Russia). HepG2 cells were cultivated in DMEM containing 10% fetal calf serum (FCS) (HyClone), 5% CO 2 at 37°C. THP-1 cells were cultivated in RPMI containing 10% FCS, 5% CO 2 at 37°C. For TNF␣ administration, HepG2 cells were seeded on 24-well plates at a density of 1 ϫ 10 4 cells/cm 2 and cultivated for 24 h. The culture medium was replaced with a fresh one without FCS, and cells were additionally incubated for 24 h before TNF␣ administration. After a 24-h incubation with TNF␣, cells were washed three times with PBS (pH 7.5), harvested, and used for RNA isolation and luciferase assays. The culture medium was used for ELISA experiments. In the experiments with NF-B and MAPK inhibitors or PPAR␣ ligands, HepG2 cells were treated with them for 1 h before TNF␣ in the following concentrations: QNZ (10 nM), JNK1/2/3 inhibitor (10 M), SB203580 (12.5 M), U0126 (10 M), WY-14643 (10 M), and MK886 (10 M). The transfection procedure using Lipofectamine 2000 (Invitrogen) was performed according to the manufacturer's instructions. 0.8 g of plasmid DNA per well of a 24-well plate were used in all experiments. The pCMVL plasmid (0.2 g) was used to control for the transfection efficiency (␤-galactosidase assay). Activity of luciferase was measured on a 20/20n luminometer (Turner Biosystems) by using a luciferase assay system (Promega, catalog no. E4030) in accordance with the manufacturer's guidelines. The luciferase activity is shown as a relative light activity, which corresponds to the percentage of light counts per minute per milligram of total protein of cell lysates relative to the control cells (relative light activity ϭ 100% in control cells). The protein concentration in cell lysates was measured with the Bradford assay.
Animals-Male C57B/6 mice were purchased from Rappolovo, the Russian Medicine Academy nursery (St. Petersburg, Russia). Mice used in experiments reported here were maintained and handled in accordance with institutional ethics committee guidelines, and these experiments were performed in concordance with the guide for the Care and Use of Laboratory Animals (29) . Mice (6 -8 weeks old, weighting 18 -22 g) were intravenously injected with 100 l of sterile PBS containing WY-14643 (1 g per 1 g of mouse weight) or DMSO (as control) and 1 g per 1 g of mouse weight of LPS (from Salmonella typhimurium) for 24 h and than sacrificed by cervical dislocation. The livers of sacrificed mice were used for RNA isolation.
PPAR␣ Knockdown in HepG2 Cells by siRNA-siRNA oligonucleotides targeted to human PPAR␣ were described previously (30) . Scrambled control RNA oligonucleotides were purchased from Santa Cruz Biotechnology (sc-37007). HepG2 cells were cultivated in DMEM containing 10% FCS for 48 h and then were transfected by siRNAs using Lipofectamine 2000 (Invitrogen) for 72 h in accordance with the manufacturer's instructions.
Reverse Transcription and Real Time PCR-RNA isolation, reverse transcription procedures, and real time PCR were described (23) . Primers for human ␤-actin, GAPDH, C3, and mouse ␤-actin and C3 were described (23) . Primers for human apolipoprotein A-I (apoA-I) were described (31) . The following primers and probe for human PPAR␣ were used: 5Ј-TCACA-AGTGCCTTTCTGTCG-3Ј, 5Ј-TCTTGGCATTCGTCCA-AAA-3Ј, and the dual-labeled probe 5Ј-ROX-GGATGTCAC-ACAACGCGATTCG-RTQ2-3Ј. The relative abundances of mRNAs of tested genes were assessed by GAPDH and ␤-actin detection in the same reaction. The levels of mRNA of genes are presented as the results of GAPDH and ␤-actin normalization as described (23) . The number of cycles (C t value) required to reach a threshold level of fluorescence that is ϳ10 S.D. values (of fluctuations in background fluorescence) above the mean background fluorescence was determined for each PCR and primer set by use of the CFX96 real time PCR system and automated software (Bio-Rad). The relative amount of mRNA (as a percentage of the control sample) was calculated by the relation 2 Ct(control)ϪCt(sample) ϫ 100. ChIP Assay-Chromatin immunoprecipitation (ChIP) was performed as described previously (31) . The following sets of primers were used: for apoA-I PPRE, 5Ј-GCTTGCTGTTTGC-CCACT-3Ј; 5Ј-GGTCCTGGCAATGTGGAA-3Ј; and dual-labeled probe 5Ј-FAM-CCCAGGGACAGAGCTGATCCTTG-BHQ1-3Ј; for the human C3 promoter region containing PPRE, 5Ј-CCATGGGGTGAGTAACCTGA-3Ј and 5Ј-TGGG-TCCAACAGAGAAAGGT-3Ј; for the human C3 promoter region containing NF-B response element (NRE), 5Ј-TTAT-CTGGCTCCTGCCTTTC-3Ј and 5Ј-CCAGGGACTGAAAA-GCTTAGG-3Ј; for the NOD1 gene, 5Ј-GGGCACACCTGTT-TTCCAG-3Ј and 5Ј-AAGTGATGCAGGACGAAGGAG-3Ј. Results were normalized, and the relative levels of PPAR␣ bound to the human apoA-I or C3 promoter and p65 bound to the human C3 promoter have been calculated as a percent of input. Antibodies against human ␤-actin were used instead of PPAR␣ or p65 antibodies as a negative control.
Nuclear Extract Preparation and EMSA-Nuclear extracts were prepared from HepG2 or THP-1 cells as described previously (32) with slight modifications. The following 5Ј-end-labeled or unlabeled with biotin synthetic oligonucleotides were purchased from Syntol (sequences of upper strands only are shown): C3-PPRE-wt, 5Ј-TGCCCTGGACTCTCCCAGGGT-CAGGGCCACCTGGTGAACACA-3Ј (corresponding to the fragment of the promoter region of the human C3 gene containing PPRE), or C3-PPRE-mut, 5Ј-TGCCCTGGACTCTCC-CATTGTCATTGCCACCTGGTGAACACA-3Ј (containing a mutation in the PPRE site; altered nucleotides are underlined) and C3-NRE, 5Ј-CTGGCTCCTGCCTTTCCCCCACT-CAG-3Ј (corresponding to the sequence of the human C3 promoter region containing NRE). EMSA was performed as described (33) . All EMSAs were performed in 15 l of total reaction volume containing 50 ng of poly(dI-dC) (Roche Applied Science), 50 g of nuclear extracts, and 50 ng of annealed biotin-labeled probes. Binding reaction was performed for 30 min at room temperature. The binding reaction mixture was separated in a 4% nondenaturing PAGE and was transferred onto a nylon (plus)membrane. Protein-bound and free probes were detected by using the streptavidin-horseradish peroxidase conjugate (Pierce) and ECL. In the competition experiments, unlabeled competitors were added to reaction mixture together with labeled probe as indicated in the figure legends.
DNA Affinity Precipitation-DNA affinity precipitation of nuclear proteins from HepG2 cells was performed by using biotin end-labeled oligonucleotide as described (34) . For the DNA affinity precipitation assay, biotin-labeled probes were incubated with nuclear extracts as described above and precipitated with streptavidin magnetic particles (Roche Applied Science). Precipitated proteins were analyzed by Western blotting with antibodies against PPAR␣ or p65.
To prove C3 promoter-dependent interactions between PPAR␣ and NF-B, the biotin-labeled fragment of the C3 promoter (Ϫ310 . . . ϩ117 relative to the transcription start point) was amplified by PCR from pC3(Ϫ310/ϩ268)-Luc (wt PPRE fragment) or from pC3(Ϫ310/ϩ268)DR0mut-Luc (mutated PPRE fragment) with the following primers: 5Ј-GGGGGTTC-TCCAGACCTTAGT-3Ј and biotin, 5Ј-GGGGGAGGTGGG-TTAGTAG-3Ј. After precipitation of DNA-protein complexes with streptavidin magnetic particles, they were cross-linked by 1% formaldehyde for 5 min with following quenching by 100 mM glycine as described (51) . Some probes were digested with HindIII restrictase and washed, and precipitated proteins were analyzed by Western blotting with antibodies against PPAR␣.
Enzyme-linked Immunosorbent Assay (ELISA)-Human complement C3 in culture medium and cell lysates were detected by sandwich ELISA with test systems purchased from Cytokine, Ltd., according to the manufacturer's instructions.
Statistical Analysis-Results are presented as means Ϯ S.E. The statistical analyses of differences between compared groups were performed using an unpaired t test or Dunnett's criterion for multiple comparisons and Kruskal-Wallis Dunn's multiple comparison test. Differences were considered statistically significant at the p Ͻ 0.05 level. Statistical analyses were performed using the program Statistica (version 5.0) and GraphPad Prism (version 6).
RESULTS

Activation of PPAR␣ Stimulates Complement C3 Expression in Human HepG2
Cells and Mouse Liver-To test whether PPAR␣ activation influences complement C3 gene expression, we treated human hepatoma cells (HepG2) with the selective PPAR␣ agonist (WY-14643) or antagonist (MK886). WY-14643 led to an increase of the level of C3 gene expression, whereas treatment of HepG2 cells with MK886 down-regulated the C3 gene (Fig. 1A) . We used PPAR␣ siRNA for estimating the PPAR␣ specificity of observed effects of the PPAR␣ ligands and, in addition to significant inhibition of both PPAR␣ mRNA (Fig. 1B) and protein (Fig. 1C) , the regulation of C3 gene by the PPAR␣ ligands was altered after treatment of HepG2 cells with PPAR␣ siRNA (Fig. 1A) . Functional knockdown of PPAR␣ blunted the stimulation of C3 gene by WY-14643 and completely abolished down-regulation of C3 gene in HepG2 cells treated with MK886 (Fig. 1A) . Similar results were observed in respect of apolipoprotein A-I (apoA-I) gene (supplemental Fig.  1 ), the well studied target gene for PPAR␣ in hepatocytes (35) . Treatment of HepG2 cells with the PPAR␣ antagonist MK886 decreased the level of C3 protein secretion (Fig. 1D ) and intracellular C3 content (Fig. 1E) . Taken together, these data show that activation of PPAR␣ positively regulates C3 expression at both mRNA and protein levels in HepG2 cells. The statistical analyses of differences between compared groups were performed using an unpaired Student's t test (*, p Ͻ 0.01; #, p Ͻ 0.05). F, the level of C3 mRNA in livers of mice intravenously injected with WY-14643 (1 g per 1 g of weight) or DMSO (as control) for 24 h. AU, arbitrary units of ␤-actin normalized C3 mRNA in mouse liver. Medians are shown. The statistical analyses of differences between compared groups were performed using a one-tailed Mann-Whitney U test (n ϭ 4).
To validate the observed positive effect of PPAR␣ activation to C3 gene expression, we used C57BL/6 mice. Intravenous treatment of mice with WY-14643 led to an increase of the level of C3 mRNA in the liver 24 h after injection (Fig. 1F) . These results indicate the conservative mechanism of C3 gene regulation by PPAR␣ in human and mouse.
PPAR␣ Binds the Human C3 Promoter in Vivo and in VitroPPARs interact with promoters of various genes as heterodimers with retinoid X receptors, and it was shown that the PPAR/retinoid X receptor heterodimer binds with the highest affinity to the direct repeat element separated by one nucleotide (DR1) and to a lesser extent to the DR0 and DR2 elements (36, 37) . To ascertain whether the C3 gene is a direct target of PPAR␣, the human C3 promoter sequence was scanned for the presence of potential PPRE sites by using nuclear receptor binding site scanning software (38) . A potential PPRE (DR0) was found between nucleotides Ϫ224 and Ϫ235 relative to the C3 gene transcription initiation site ( Fig. 2A, supplemental Fig.  2 ). EMSA was performed to test the ability of nuclear proteins from HepG2 cells to bind with the putative (Ϫ224/Ϫ235)C3-PPRE (Fig. 2B ). The binding of nuclear proteins to the probe was specific because the complex was depleted by an excess of the unlabeled C3-PPRE oligonucleotide but not by an excess of the unlabeled mutated C3-PPRE oligonucleotide (Fig. 2B) . Antibodies against PPAR␣ led to a depletion of the C3-PPRE oligonucleotide-protein complex (Fig. 2B ). To prove PPAR␣ interaction with (Ϫ224/Ϫ235)C3-PPRE, we used DNA affinity precipitation assay using nuclear proteins from HepG2 cells and biotin-labeled probe containing (Ϫ224/Ϫ235)C3-PPRE. Western blot analysis of precipitated proteins showed that PPAR␣ interacts with (Ϫ224/Ϫ235)C3-PPRE, and an excess of the unlabeled C3-PPRE oligonucleotide but not unlabeled mutated C3-PPRE oligonucleotide decreased the level of PPAR␣ into the precipitate (Fig. 2C) . These data show that the human C3 promoter contains a functional PPRE, which is able to bind PPAR␣. Interestingly, alignment of sequences of the human and mouse 5Ј-region of the C3 gene indicated that the PPRE site is conserved between human and mouse C3 promoters (supplemental Fig. 2) . These results confirm the evolutionary conserved mechanism of C3 gene regulation by PPAR␣ in hepatocytes among human and mouse.
To validate the binding of PPAR␣ to the human C3 promoter in vivo, a ChIP assay with anti-PPAR␣ antibodies was performed with HepG2 cells. As a negative control, the anti-␤-actin antibodies were used. The essential enrichment of the specific PCR signal was identified with primers specific for the human C3 promoter and apoA-I promoter (positive control) in the precipitate with anti-PPAR␣ antibodies versus anti-␤-actin ones in HepG2 cells (Fig. 2D) . In the same experiment, there was no any enrichment of PCR signal with primers specific for the human NOD1 gene (negative control).
The PPRE into the Human C3 Promoter Is Necessary for Regulation of C3 Gene by PPAR␣-Recently, we described the DR4 site in the human C3 promoter that is involved in positive regulation of C3 gene by liver X receptors in human macrophages but not in HepG2 cells (supplemental Fig. 2) (23) . However, DNA affinity precipitation assay did not allow us to show interaction of PPAR␣ with the DR4 site in HepG2 cells (data not shown). Moreover, plasmid pC3(Ϫ463/ϩ268)-Luc containing the DR4 site and truncated plasmid pC3(Ϫ310/ϩ268)-Luc lacking the DR4 site were both activated by WY-14643 and suppressed by MK886 (Fig. 1E) . These results show that the DR4 site is not involved in the regulation of C3 gene by PPAR␣. By contrast, disruption of the DR0 site by site-directed mutagenesis or deletion of the DR0 site abolished the effects of WY-14643 or MK886 to the activity of the C3 promoter (Fig.  2E) . Moreover, inactivation of the DR0 site led to strong downregulation of the C3 promoter activity (Fig. 2E) . These data show that the DR0 site is a functional PPRE that is important for regulation of C3 gene by PPAR␣ and suggest that PPAR␣ is significant for maintaining of high level of C3 expression in hepatocytes.
TNF␣ Stimulates C3 Expression via NF-B and MEK1/2 Signaling Pathways in HepG2
Cells-TNF␣ is known as the main positive regulator of C3 expression during acute response in hepatocytes (9, 10) . However, the mechanism of TNF␣-mediated up-regulation of C3 gene, including involved signaling pathways and transcription factors, is not elucidated. We showed that treatment of HepG2 cells with TNF␣, as expected, stimulates C3 gene expression (Fig. 3A) and protein secretion (Fig. 3B ) in a dose-dependent manner. Inhibition of NF-B abolished TNF␣-mediated activation of C3 gene expression in HepG2 cells (Fig. 3C) . Inhibition of MEK1/2 increased the level of basal expression of C3 gene and diminished the level of activation of C3 expression by TNF␣ (Fig. 3C ). According to our results, JNK and p38 signaling pathways seem to be not involved in TNF␣-mediated up-regulation of the C3 gene in HepG2 cells (Fig. 3C) . Similarly, NF-B and MEK1/2 were shown to be important for the TNF␣-induced increase of C3 protein content in HepG2 cells, whereas JNK and p38 are not (Fig. 3D) . At the same time, inhibition of MEK1/2, JNK, or p38 signaling pathways blocked an increase of C3 secretion by TNF␣-treated HepG2 cells, but NF-B appeared to be not important for the process (Fig. 3E) . Interestingly, inhibition of JNK or p38 led to a decrease of both intracellular or secreted C3 protein (Fig. 3, D and E) but did not affect C3 transcription (Fig.  3C) , suggesting involvement of the JNK and p38 signaling pathways in stimulation of C3 translation and/or protein stabilization. Taken together, these data show that TNF␣ stimulates C3 transcription primarily through NF-B and partly through MEK1/2, whereas the TNF␣-mediated increase of C3 secretion depends on MEK1/2, JNK, and p38 signaling pathways.
To test whether NF-B and MEK1/2 are involved in activation of C3 gene transcription in HepG2 cells treated with TNF␣, or these signaling pathways participate in TNF␣-mediated stabilization of C3 mRNA, we transfected HepG2 cells with plasmid containing luciferase gene under the control of the Ϫ310/ϩ268 region of the human C3 promoter. As in the case of endogenous C3, the activity of the plasmid was activated by TNF␣, whereas inhibition of MEK1/2 partly and NF-B completely abrogated TNF␣-mediated activation of the human C3 promoter (Fig. 3F) . These results support supposition that the human C3 gene is regulated by TNF␣-NF-B/MEK1/2 axis at the transcriptional level, moreover, show that the Ϫ310/ ϩ268 region of the human C3 promoter contains target site(s) for the regulation.
The Human C3 Promoter Contains NF-B Response Element
That Binds p65-Analysis of the human C3 promoter Ϫ310/ ϩ268 region sequence allowed us to find the potential NRE between nucleotides Ϫ37 and Ϫ52 relative to the C3 gene transcription initiation site (supplemental Fig. 2) . EMSA was performed to test the ability of nuclear proteins from HepG2 cells to bind to the putative NRE (Fig. 3G ). The binding of nuclear proteins of TNF␣-treated HepG2 cells to the probe was specific because the complex was depleted by an excess of the unlabeled C3-NRE oligonucleotide (Fig. 3G) . Nuclear proteins of TNF␣-untreated HepG2 cells formed only weak band corresponding to the C3-NRE-protein complex (Fig. 3G) . One of the important components of the NF-kB complex is p65 (also known as RelA) that interacts with NRE of the target gene as a heterodimer with p50 (39) . To prove p65 interaction with the NRE within the human C3 promoter, we used DNA affinity precipitation assay using nuclear proteins from HepG2 cells and biotin-labeled probe containing (Ϫ37/Ϫ52)C3-NRE. Western- blot analysis of precipitated proteins showed that p65 interacts with (Ϫ37/Ϫ52)C3-NRE in the case of TNF␣-treated and, to a lesser extent, TNF␣-untreated HepG2 cells (Fig. 3H) .
To validate the binding of p65 to the human C3 promoter in vivo, a ChIP assay with anti-p65 antibodies was performed with HepG2 cells. As a negative control, the anti-␤-actin antibodies were used. The essential enrichment of the specific PCR signal was identified with primers specific for the human C3 promoter in the precipitate with anti-p65 antibodies versus anti-␤-actin ones in HepG2 cells (Fig. 3I) . In the same experiment, there was not enrichment of PCR signal with primers specific for the human NOD1 gene (negative control).
WY-14643 Inhibits TNF␣-mediated Up-regulation of C3 Gene in a PPAR␣-dependent Manner-Activation of PPAR␣ is
known to be associated with negative regulation of various proinflammatory genes (28) . We showed that activation of PPAR␣ with WY-14643 inhibits the TNF␣-mediated stimulation of C3 gene transcription, whereas treatment of HepG2 cells with the PPAR␣ antagonist MK886 in turn increases the ratio of C3 up-regulation by TNF␣ (Fig. 4, A and B) . At the same time, WY-14643 did not diminish the TNF␣-mediated up-regulation of C3 gene in HepG2 cells treated with PPAR␣ siRNA (Fig. 4C) . These results show that WY-14643 inhibits the positive regulatory effect of TNF␣ toward the C3 gene in a PPAR␣-dependent manner. Moreover, treatment of HepG2 cells with WY-14643 inhibited the TNF␣-mediated stimulation of C3 protein synthesis and secretion, whereas MK886 does not influence the process (Fig. 4, D and E) .
PPAR␣ and TNF␣ Show Reciprocal Down-regulation at the Human C3 Promoter-An anti-inflammatory action of PPAR␣ is shown to be associated with negative cross-talk with NF-B (40) . As expected, treatment of HepG2 cells with TNF␣ led to an increase of the level of p65 binding with the human C3 promoter (Fig. 4F) . The PPAR␣ agonist WY-14643 did not alter p65 binding with the human C3 promoter in TNF␣-untreated HepG2 cells but reduced the level of TNF␣-mediated increase of p65 bound to the human C3 promoter (Fig. 4F) . These data show that the mechanism of PPAR␣-dependent inhibition of the TNF␣-mediated up-regulation of C3 gene may be realized at least partly via reduction of the efficiency of p65 binding with the human C3 promoter.
TNF␣ down-regulated PPAR␣ gene expression in HepG2 cells in a dose-dependent manner (Fig. 4G) . Treatment of HepG2 cells with TNF␣ led to a decrease of PPAR␣ protein content in the cells (Fig. 4H) . Inhibition of NF-B or MEK1/2 signaling pathways prevented the TNF␣-mediated decrease of PPAR␣ protein content (Fig. 4H) . Interestingly, simultaneous treatment of HepG2 cells with TNF␣ and the PPAR␣ agonist WY-14643 led to an abrogation of the positive regulation of the C3 gene by each of those molecules (Fig. 4A) . Because activation of PPAR␣ inhibits TNF␣-mediated up-regulation of C3 gene and, in turn, TNF␣ decreases the level of PPAR␣ via NF-B or MEK1/2 signaling pathways, we suggested that this reciprocal inactivation is responsible for the abolition of the effects of TNF␣ and PPAR␣ toward C3 expression. In support of this suggestion, we showed that TNF␣ does not diminish the level of ChIP assay showed that treatment of HepG2 cells with TNF␣ significantly reduces the level of PPAR␣ binding with the human C3 promoter (Fig. 4I) , which corresponded to a decrease of PPAR␣ protein into the cells (Fig. 4H) . Taken together, these result show mutual down-regulation of TNF␣-and PPAR␣-driven effects at the human C3 promoter and possibly suggest a negative feedback loop involved in the mechanism of control of C3 expression at the acute phase of inflammation and prevention of overstimulation of the C3 gene by TNF␣.
A PPAR␣ Ligand WY-14643 Prevents LPS-mediated Up-regulation of C3 Gene in Mouse
Liver-To test a physiological role of PPAR␣ in the stimulation of C3 expression, we used LPStreated mouse model because it is known that injection of LPS leads to an increase of proinflammatory cytokine concentrations in the plasma and thereby to up-regulation of C3 gene in the liver (8) . Injection of LPS led to an increase of the level of C3 gene expression in the liver in DMSO-treated mice, whereas treatment of mice with WY-14643 completely abrogated stimulatory effects of LPS (Fig. 5) . Interestingly, simultaneous injection of both LPS and WY-14643 resulted in abolishment of stimulatory effect of each compounds toward the C3 gene (Fig.  5) , which is similar to observed effects of TNF␣ and WY-14643 in the regulation of the human C3 gene in HepG2 cells (Fig. 4,  A-C) . These data show that ligand-dependent activation of PPAR␣ is involved in the control of C3 expression in the liver during acute phase response.
PPRE within the Human C3 Promoter Is Important for the PPAR␣-mediated Inhibition of the TNF␣-induced Activation of C3 Gene Transcription-Multiple mechanisms are described to account for the anti-inflammatory action of PPARs, including inhibition of NF-B and AP-1 transcription activities, prevention of the signal-dependent turnover of the nuclear co-repressor from inflammatory response genes and others (41) . Some of the mechanisms do not require PPRE in the target gene promoter; however, the presence of the functional PPRE in the human C3 promoter allowed us to test the role of the PPRE in PPAR␣-mediated inhibition of the TNF␣-induced activation of C3 gene transcription. Activation of PPAR␣ by WY-14643 abrogated up-regulation of plasmids pC3(Ϫ463/ϩ268)-Luc and pC3(Ϫ310/ϩ268)-Luc, which contain the PPRE in TNF␣-treated HepG2 cells (Fig. 6A) . In contrast, disruption of the PPRE by site-directed mutagenesis (pC3(Ϫ310/ϩ268)DR0mu-t-Luc) or deletion of the PPRE (pC3(Ϫ166/ϩ268)-Luc) led to abolition of the PPAR␣-mediated inhibition of the TNF␣ effect (Fig. 6A) . These data show that the PPRE into the human C3 promoter is important for anti-inflammatory action of PPAR␣ in HepG2 cells.
PPAR␣ Physically Interacts with p65 on the Human C3 Promoter-Because PPRE into the human C3 promoter is important for PPAR␣-dependent abrogation of TNF␣-mediated activation of the C3 gene, we tested whether PPAR␣ interacts with p65 at the C3 promoter. Therefore, we performed protein precipitation from HepG2 cell nuclear extracts using biotin 5Ј-end-labeled fragment of the human C3 promoter sequence containing the PPRE and NRE separated with the HindIII restriction site (Fig. 6B ). As expected, PPAR␣ was precipitated with undigested probe, but it was also detected in the precipitate of HindIII-treated fragment, showing PPAR␣-p65 interaction (Fig. 6B) . Disruption of PPRE by site-directed mutagenesis, which prevents PPAR␣ binding (Fig. 2, B and C) , did not eliminate PPAR␣ completely from C3 promoter, which suggests the existence of PPRE-independent PPAR␣-p65 interactions. Pretreatment of HepG2 cells with WY-14643 did not change PPAR␣ precipitated with the wt PPRE-containing fragment but dramatically decreased PPAR␣ binding with the PPRE-mutated fragment, indicating ligand-independent mechanism of PPRE-mediated PPAR␣-p65 interaction on C3 promoter and ligand-dependent mechanism of PPRE-independent PPAR␣-p65 interactions (Fig. 6B) . Therefore, our data indicate that 1) PPAR␣ can bind p65 at the C3 promoter in both WY-14643-treated and untreated HepG2 cells and 2) PPRE increases the intensity of PPAR␣-p65 interaction at the C3 promoter. These findings are in correspondence with data that PPRE is necessary for ligand-dependent PPRA␣-mediated inhibition of TNF␣ effects toward C3 transcription (Fig. 6A) . Taken together, these data suppose the "five-step" model of PPAR␣-mediated inhibition of TNF␣-p65-dependent up-regulation of the C3 gene: 1) PPAR␣ binds the PPRE within the C3 promoter and up-regulate C3 expression in a ligand-dependent manner; 2) in TNF␣-treated cells, p65 binds the NRE; 3) PPRE-bound PPAR␣ interacts with p65; 4) ligand-dependent activation of PPAR␣ leads to abrogation of transcription-driven effects of p65, probably due to co-activator competition or co-repressor turnover inhibition; and 5) TNF␣ down-regulates PPAR␣ expression and binding with the PPRE within the C3 promoter, realizing thereby that negative feedback allows p65 to escape the inhibition by PPAR␣ at the C3 promoter if proinflammatory stimuli are strong (Fig. 7) .
PPAR␣ Is Involved in the Regulation of C3 Gene in THP-1 Monocytes-Treatment of THP-1 cells with TNF␣ led to a stimulation of C3 gene expression (supplemental Fig. 4A ). Inhibition of p38, MEK1/2, or NF-B signaling pathways partly Fig. 4B ) but did not lead to complete inhibition of the effect of TNF␣ as it was observed in HepG2 cells (Fig. 4A) . ChIP assay showed that PPAR␣ binds with the human C3 promoter in THP-1 monocytes (supplemental Fig. 4C ). These data show that PPAR␣ is involved in regulation of the C3 gene in human hepatocytes and monocytes.
DISCUSSION
A principal finding of the present study is that activation of PPAR␣ positively regulates complement C3 gene expression in human HepG2 cells and in mouse liver. It is shown that PPAR␣ regulates the expression of dozens of genes in the liver through a PPRE-dependent mechanism as well as a number of genes The statistical analyses of differences between compared groups (control or treated HepG2 cells) were performed using an unpaired Student's t test (*, p Ͻ 0.05). B, DNA affinity precipitation assay from HepG2 cell nuclear extracts using biotin 5Ј-end-labeled fragment of human C3 promoter that contains the PPRE (Biot. C3 Probe wt) or mutated PPRE (Biot. C3 Probe mut) and NRE separated with HindIII restriction site. HepG2 cells were treated with TNF␣ and treated or not with WY-14643 (WY, 10 M) for 24 h. After nuclear protein binding, probes were precipitated with anti-biotin beads, cross-linked by formaldehyde, and digested or not with HindIII (marked by ϩ in the case of treatment with HindIII) (see "Experimental Procedures" for details). Proteins from precipitates and supernatants (S) were analyzed by Western blot using antibody against human PPAR␣. Biot. control probe, biotin-labeled site B from human apolipoprotein A-I hepatic enhancer (binds with HNF3␤; negative control). Arbitrary units (AU) determined by densitometry of PPAR␣ bands are shown.
that are still not reported as containing a functional PPRE, and the majority of this genes are involved in fatty acids oxidation and lipid metabolism (24) . Nevertheless, the role of PPAR␣ in regulation of complement system genes in the liver remains to be established. Because the liver is the main source of C3 in circulation (3), regulation of C3 gene expression and secretion by hepatocytes is of special interest. The C3 gene is known as the direct target for farnesoid X receptor in hepatocytes (22) and liver X receptors in macrophages (23) , and finding that PPAR␣ directly regulates C3 gene via PPRE into the C3 promoter broadens our understanding about mechanisms connecting metabolic processes, nuclear receptors, and complement system.
More than two decades ago, C3 expression was shown to be activated by TNF␣ during acute response in hepatocytes (9, 10) . Here, we showed for the first time the NF-B/MEK1/2-dependent mechanism of up-regulation of C3 gene by TNF␣ in HepG2 cells. As in the case of many other positive acute phase genes, TNF␣-dependent activation of C3 is primarily controlled by NF-kB, whereas stimulation of C3 protein secretion is controlled by MEK1/2, p38, and JNK signaling pathways in TNF␣-treated HepG2 cells. Canonical activation of NF-B by TNF␣ leads to nuclear localization and target gene promoter binding of p65/p50 heterodimer, which stimulates the expression of a variety of inflammation-induced genes (42) . We found the NRE in the human C3 promoter that binds p65. Interestingly, we showed that ligand-dependent activation of PPAR␣ inhibits TNF␣-mediated up-regulation of C3 gene, via, at least partly, decreasing of p65 binding with the human C3 promoter in HepG2 cells. In contrast, our results show that the PPRE-bound PPAR␣ physical interaction with p65 into the human C3 promoter is necessary for abolishment of TNF␣-mediated stimulation of C3 gene transcription by the PPAR␣ agonist WY-14643. Several nuclear receptors, including PPARs, can inhibit NF-B-dependent activation of inflammation-induced genes using a mechanism known as transrepression, which typically involves indirect association (tethering) of the nuclear receptors with target genes rather than direct sequence-specific DNA binding (43) . In the case of the human C3 promoter, however, sequencespecific DNA binding of PPAR␣ seems to be involved in repression of TNF␣ effects toward C3 expression, as deletion or disruption of the PPRE led to a decrease of PPAR␣-p65 interaction into the C3 promoter and abrogation of interference between PPAR␣ and TNF␣ pathways.
The role of PPARs in inflammatory processes and mechanisms of anti-inflammatory action of PPAR ligands are broadly discussed (44) . There are a number of reports that describe transrepression on gene expression by PPAR␣ through interference with NF-B signaling pathway, including but not limited by cytokine-induced vascular cell adhesion molecule-1 (45) and endothelin-1 (46) . Furthermore, PPAR␣ ligands repress acute phase proteins such as fibrinogene (47) . PPAR␣ may be activated by several fatty acid metabolites that are produced during inflammatory response, for example, leukotriene B4 and 8S-hydtoxeicosatetraenoic acid (25, 48) . These observations suggest that PPAR␣ may function as a sensor and regulator of inflammatory responses via its ability to be activated by locally generated eicosaniods (49) . In contrast, PPAR␣ expression is suppressed during the hepatic acute phase response (50) . These data suggest negative feedback loop, limiting on the one part activation of certain positive acute phase proteins in the liver and decreasing at the same time PPAR␣ activity as a negative acute phase protein. Our data obtained from human HepG2 cell and mouse liver models show that TNF␣-induced activation of C3 gene in hepatocytes is controlled by this double-edged mechanism involving PPAR␣, probably to prevent overstimulation of the C3 gene during acute inflammation. Moreover, we show that activation of NF-B and MEK1/2 signaling pathway by TNF␣ is involved in down-regulation of PPAR␣ protein content in HepG2 cells.
Taken together, our data show a novel mechanism of PPAR␣-dependent regulation of C3 gene expression and protein secretion by HepG2 cells. Moreover, we show NF-B-mediated activation of C3 expression in HepG2 cells treated with TNF␣ and found interference between PPAR␣ and TNF␣ signaling pathways during regulation of the C3 gene. These results suggest a novel mechanism controlling C3 expression in hepatocytes during acute phase inflammation and demonstrate a cross-talk between PPAR␣ and TNF␣ in the regulation of complement system. 
